Essential n-3 fatty acids in cardiac insufficiency and heart...

Details Essential n-3 fatty acids in cardiac insufficiency and heart... Essential n-3 fatty acids in cardiac insufficiency and heart...

2006-01-17

2008-10-21

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S560000

Reexamination Certificate

active

07439267

ABSTRACT:
The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination with another therapeutic agent.

REFERENCES:
patent: 5502077 (1996-03-01), Breivik et al.
patent: 5760081 (1998-06-01), Leaf et al.
patent: 6140304 (2000-10-01), Sears
patent: 2291959 (2001-06-01), None
patent: 1082909 (1994-03-01), None
patent: 273852 (1989-11-01), None
patent: 10056351 (2002-05-01), None
patent: 0 292 846 (1988-11-01), None
patent: 0 780 124 (2001-12-01), None
patent: 0 760 393 (2003-06-01), None
patent: 1 157 692 (2005-10-01), None
patent: 2090529 (1982-07-01), None
patent: 2 221 843 (1990-02-01), None
patent: 1274734 (1997-07-01), None
patent: 4182426 (1992-06-01), None
patent: 8053350 (1996-02-01), None
patent: 8151334 (1996-06-01), None
patent: 2001-247457 (2001-09-01), None
patent: WO 87/03899 (1987-07-01), None
patent: WO 94/20092 (1994-09-01), None
patent: WO 96/31457 (1996-10-01), None
patent: WO 96/34846 (1996-11-01), None
patent: WO 96/34855 (1996-11-01), None
patent: WO 00/48592 (2000-08-01), None
patent: WO 01/03696 (2001-01-01), None
patent: WO 01/36369 (2001-05-01), None
patent: WO 01/52822 (2001-07-01), None
patent: WO 01/60778 (2001-08-01), None
patent: WO 01/76568 (2001-10-01), None
patent: WO 02/02105 (2002-01-01), None
Hazra et al., “Pharmacology and Therapeutic Potential of the n-3 Polyunsaturated Fatty Acids, Eicosapentaenoic Acid (EPA) and Docosahexaenoic acid (DHA) in Fish Oils”, Indian Journal of Pharmacology, 1999; 31:247-264.
British National Formulary, No. 8, 1989, Chapter 2: Cardiovascular System, British Medical Association and the Royal Pharmaceutical Society of Britain.
Burr, et al., “Effects on Changes in Fat, Fish, and Fibre Intakes on Death and Myocardial Reinfarction: Diet and Reinfarction Trial (DART)”, The Lancet, 1989:757-761.
Burr, et al., “Diet and Reinfarction Trial (DART): Design, Recruitment, and Compliance”, European Heart Journal, vol. 10, 1989:558-567.
Luley, et al., “Bioavailability of Omega-3 Fatty Acids: Ethylester Preparations are as Suitable as Triglyceride Preparations”, Akt. Ernähr.—Med., vol. 15, 1990:123-125.
Norday, et al., “Absorption of the n-3 Eicosapentaenoic and Docosahexaenoic Acids as Ethyl Esters and Triglycerides by Humans1-3”, Am J Clin Nutr, vol. 53, 1991:1185-1190.
Schmidt, et al., “n-3 Fatty Acids: Prevention and Treatment in Vascular Disease”, Bi & Gi Publishers, Springer Verlag, London, 1995.
Singh, et al., “Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil and Mustard Oil in Patients with Suspected Acute Myocardial Infarction: The Indian Experiment of Infarct Survival—4”, Cardiovascular Drugs and Therapy, vol. 11, 1997:485-491.
GISSI-Prevenzione Investigators, “Dietary Supplementation with N-3 Polyunsaturated Fatty Acids and Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial”, The Lancet, vol. 354, 1999:447-455.
Marchioli, et al., “The Results of the GISSI-Prevenzione trial in the General Framework of Secondary Prevention”, European Heart Journal, vol. 21, Issue 12, 2000:949-952.
R. Marchioli, “Treatment with n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Results of GISSI-Prevenzione Trial”, European Heart Journal Supplements, vol. 3, (Suppl. D), 2001:D85-D97.
Zarain-Herzberg, et al., “Transcriptional Modulators Targeted at Fuel Metabolism of Hypertrophied Heart”, Am. J. Cardiology, 1999; 83:31H-37H.
McCarty, “Fish Oil and Other Nutritional Adjuvants for Treatment of Congestive Heart Failure,” Medical Hypothesis, 46, 1996, p. 400-406.
“Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) randomised controlled trial,” Articles, 140, 2005, pp. 1-13.
Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone, JAMA, 283(15), 2000, pp. 1967-1975.
S. Takeo, et al., “Effects of long-term treatment with eicosapentaenoic acid on the heart subjected to ischemia/reperfusion and hypoxia/reoxygenation in rats”, Molecular and Cellular Biochemistry, vol. 188(1-2), Nov. 1998: pp. 199-208.
Gualler, Eliseo et al: “Omega-3 fatty acids in adipose tissue and risk of myocardial infarction: the EURAMIC study” Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19 (4), pp. 1111-1118.
Rissanen Tiina et al: “Fish oil-derived fatty acids, docosahexanoic acid and docosapentaenoic acid, and the risk of acute coronary events: The Kupio Ishaemic Heart Disease Risk Factor Study.” CIRCULATION, vol. 102, No. 22, Nov. 28, 2000 (2000-11-28), pp. 2677-2679.
Rissanen T H (Reprint) et al: “Fish oil derived fatty acids, docasahexanoic acid and docosapentaenoic acid and the risk of acute myocardial infarction”CIRCULATION, (Oct. 27, 1998) vol. 98, No. 17, Supp. Äsü, pp. 2823-2823.
McCarty,M.F., “Fish Oil and Other Nutritional Adjuvants for Treatment of Congestive Heart Failure,” Medical Hypotheses, 1996 vol. 46, pp. 400-406.
L.M. Freeman, et al., “Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure”, Journal of veterinary internal medicine/American College of veterinary Internal Medicine, vol. 12(6), Dec. 1998: pp. 440-448.
M.A. Silver, et al., “Difficult cases in heart failure: Cardiac cachexia in advanced heart failure: Suppression of tumour necrosis factor by omega-3 fatty acids”, Congestive Heart failure, vol. 4 (5), Nov. 1998: pp. 44-45.
Milani et al., “Can Pharmacologic Modulation of Tumor Necrosis Factor α in Advanced Heart Failure with Cachexia Result in Anabolic Effects?,”J. Heart and Lung Transplant. 15, S85, Abstract 185, 1996.
Toyofuku, Study on protection of ischemic myocardium and arrest of ventricular arrhythmia by omega-3 polyunsaturated fatty acid intake, Jpn. Cir. J., 58, 99. 903-912, 1994.
Kinoshita I. et al., “Antiarrhythmic Effects of Eicosapentaenoic Acid During Myocardial Infarction.” Jpn. J. Clin. Physiol., 26, pp. 25-33, 1996.
Lands W., “Fish and Human Health”, Academic Press, Inc. 1986.
Billman, et al., “Prevention of ischemia-induced ventricular fibrillation by ω-3 fatty acids”, Proc. Natl. Acad. Sci. USA, vol. 91, May 1994: pp. 4427-430.
Ullmanns Encyklopädie der technischen Chemie, 4. Auglage, 1976, band 12, Seite 630: Herz-und Krieslaufmittel: g-Strpohantin.
Merck Manual, 13thEdition, 1997, pp. 403-416.
Merck Manual, 17thEdition, 1999, pp. 1740-1741.
Harrison's Principles of Internal Medicine, 15thEd., pp. XIV, 1318-1322, 1374 (date unavailable).
A. Nordøy, et al., “n-3 polyunsaturated fatty acids and cardiovascular diseases”, Lipids, vol. 36, 2001: pp. 127-129.
M.de Lorgeril, et al., Diet and medication for heart protection in secondary prevention of coronary heart disease. New concepts., Nutrition, metabolism, and cardiovasular diseases-NMCD, vol. 10 (4), Aug. 2000: pp. 216-222.
S.Sane, et al., “Eicosapentaenoic acid reduces pulmonary edema in endotoxemic rats,” Journal of surgical research, vol. 93 (1). Sep. 2000: pp. 21-27.
W.S. Harris, et al., “safety and efficacy of Omacor in severe hypertriglyceridemia”, Journal of cardiovascular risk, vol. 4(5-6), Dec. 1997: pp. 385-391.
G. Balestrieri, et al., “Fish oil supplementation in patients with heterozygous famillal hypercholesterolemia”, Recenti progessi in medicinia, vol. 87 (3), Mar. 1996: pp. 102-105.
P. McLennan, et al., “The cardiovascular protective role of docosahexaenoic acid”, European Journal of Pharmocology, 300 (1996) pp. 83-89.
D.W.

Affiliated with

Also associated with

Rating

Essential n-3 fatty acids in cardiac insufficiency and heart... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Essential n-3 fatty acids in cardiac insufficiency and heart..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Essential n-3 fatty acids in cardiac insufficiency and heart... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4000165